Latest news
NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)
NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, today announces dosing of the first patient with...
FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019
Ghent, Belgium, 23 September 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology...
NorthSea Therapeutics strengthens its management team with the appointment of Mats Blom as CFO
Naarden, The Netherlands, 4 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, today announces the appointment of...
Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer
Maastricht, The Netherlands, 1st August 2019 – Cristal Therapeutics, a Phase 2 clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces that Dr Werner Cautreels is...
Next events
BioEntrepreneurship Summit – October 15/16
Daniela will attend the BioEntrepreneurship Summit in Munich.http://www.bioentrepreneurshipsummit.org
Lisbon Investor Conference – November 8
Daniela will attend the Health Startup Day at the Lisbon Investor Conference in Lisbon https://lisboninvestorconference.com/en/
BIO-Europe Hamburg – November 11/ 13
BGV will attend the BIO-Europe in Hamburg. https://ebdgroup.knect365.com/bioeurope/
Latest investments
